Aclaris Therapeutics Valuation
Is 0H8T undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0H8T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0H8T's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0H8T's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0H8T?
Key metric: As 0H8T is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0H8T's PS Ratio? | |
|---|---|
| PS Ratio | 8.3x |
| Sales | US$27.08m |
| Market Cap | US$146.43m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0H8T's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.4x | ||
ANCR Animalcare Group | 1.9x | 3.8% | UK£143.1m |
REDX Redx Pharma | 13.9x | -37.6% | UK£58.3m |
APH Alliance Pharma | 1.4x | 5.2% | UK£248.7m |
EAH ECO Animal Health Group | 0.5x | 5.9% | UK£44.0m |
0H8T Aclaris Therapeutics | 8.3x | 13.0% | US$146.4m |
Price-To-Sales vs Peers: 0H8T is expensive based on its Price-To-Sales Ratio (8.3x) compared to the peer average (4.4x).
Price to Sales Ratio vs Industry
How does 0H8T's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
EAH ECO Animal Health Group | 0.5x | 5.9% | US$55.52m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 0H8T is expensive based on its Price-To-Sales Ratio (8.3x) compared to the European Pharmaceuticals industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is 0H8T's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.3x |
| Fair PS Ratio | 0.3x |
Price-To-Sales vs Fair Ratio: 0H8T is expensive based on its Price-To-Sales Ratio (8.3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.65 | US$5.00 +89.0% | 92.7% | US$13.00 | US$2.00 | n/a | 4 |
| Nov ’25 | US$2.00 | US$1.55 -22.5% | 29.4% | US$2.00 | US$1.00 | n/a | 4 |
| Oct ’25 | US$1.17 | US$1.55 +33.0% | 29.4% | US$2.00 | US$1.00 | n/a | 4 |
| Sep ’25 | US$1.17 | US$1.55 +32.6% | 29.4% | US$2.00 | US$1.00 | n/a | 4 |
| Aug ’25 | US$1.33 | US$1.84 +38.6% | 38.5% | US$3.00 | US$1.00 | n/a | 5 |
| Jul ’25 | US$1.27 | US$1.84 +44.9% | 38.5% | US$3.00 | US$1.00 | n/a | 5 |
| Jun ’25 | US$1.03 | US$1.84 +79.5% | 38.5% | US$3.00 | US$1.00 | n/a | 5 |
| May ’25 | US$1.23 | US$1.80 +46.3% | 41.6% | US$3.00 | US$1.00 | n/a | 5 |
| Apr ’25 | US$1.25 | US$1.80 +44.0% | 41.6% | US$3.00 | US$1.00 | n/a | 5 |
| Mar ’25 | US$1.21 | US$6.17 +410.5% | 158.7% | US$28.00 | US$1.00 | n/a | 6 |
| Feb ’25 | US$1.24 | US$6.17 +397.3% | 158.7% | US$28.00 | US$1.00 | n/a | 6 |
| Jan ’25 | US$1.06 | US$6.81 +543.3% | 124.8% | US$28.00 | US$1.00 | n/a | 8 |
| Dec ’24 | US$0.90 | US$7.57 +737.0% | 116.6% | US$28.00 | US$1.00 | n/a | 7 |
| Nov ’24 | US$4.98 | US$29.78 +497.9% | 23.0% | US$43.00 | US$20.00 | US$2.00 | 9 |
| Oct ’24 | US$6.78 | US$30.75 +353.6% | 21.6% | US$43.00 | US$20.00 | US$1.17 | 8 |
| Sep ’24 | US$7.87 | US$28.89 +267.1% | 27.5% | US$43.00 | US$16.00 | US$1.17 | 9 |
| Aug ’24 | US$9.82 | US$28.89 +194.2% | 27.5% | US$43.00 | US$16.00 | US$1.33 | 9 |
| Jul ’24 | US$10.60 | US$28.89 +172.6% | 27.5% | US$43.00 | US$16.00 | US$1.27 | 9 |
| Jun ’24 | n/a | US$28.89 0% | 27.5% | US$43.00 | US$16.00 | US$1.03 | 9 |
| May ’24 | n/a | US$29.11 0% | 30.3% | US$43.00 | US$11.00 | US$1.23 | 9 |
| Apr ’24 | US$8.44 | US$29.11 +245.1% | 30.3% | US$43.00 | US$11.00 | US$1.25 | 9 |
| Mar ’24 | US$12.10 | US$32.89 +171.8% | 22.0% | US$50.00 | US$25.00 | US$1.21 | 9 |
| Feb ’24 | US$16.93 | US$32.50 +92.0% | 23.3% | US$50.00 | US$25.00 | US$1.24 | 8 |
| Jan ’24 | n/a | US$31.89 0% | 23.1% | US$50.00 | US$25.00 | US$1.06 | 9 |
| Dec ’23 | US$15.91 | US$32.25 +102.7% | 24.0% | US$50.00 | US$25.00 | US$0.90 | 8 |
| Nov ’23 | n/a | US$33.29 0% | 23.2% | US$50.00 | US$26.00 | US$4.98 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Formycon
€820.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€46.50
7D
-3.8%
1Y
-26.2%
hVIVO
UK£172.8m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.25
7D
-10.9%
1Y
39.6%
Dermapharm Holding
€1.9b
Manufactures and sells off-patent branded pharmaceutical products in Germany.
0A5J
€34.35
7D
7.7%
1Y
-14.5%